India Globalization Capital Inc (IGC) represents a strong commitment to innovation, growth, and value creation. With a focus on rapidly expanding markets, IGC leverages its expertise in developing and commercializing transformative products and solutions. The company's corporate philosophy centers around delivering exceptional shareholder value, fostering long-term partnerships, and adhering to the highest standards of corporate governance and ethics. By staying attuned to market trends and continuously enhancing its offerings, IGC stands as a leading player in sectors like cannabis-based therapies, specialty pharmaceuticals, and infrastructure. IGC's dedication to excellence and strategic approach underscores its mission to enhance the lives of millions through pioneering technologies and forward-thinking strategies.

India Globalization Capital Inc (IGC) is primarily present in India and the United States. With its headquarters in Bethesda, Maryland, USA, IGC operates in various states across India and has a significant presence in its home country. The company focuses on developing and commercializing cannabis-based pharmaceutical and natural wellness products, as well as providing services to the telecommunications and infrastructure sectors. As a global player, IGC aims to leverage its expertise and strategic partnerships to expand its presence in other regions and countries, capitalizing on emerging market opportunities worldwide.

India Globalization Capital Inc (IGC) has achieved several significant milestones over the years. One of the notable achievements is the company's entry into the medical cannabis market. By leveraging its expertise in plant-based therapies and advanced pharmaceutical technologies, IGC has developed a portfolio of cannabinoid-based combination therapies. This pioneering move has positioned the company uniquely in the industry, creating opportunities for substantial growth and market penetration. Moreover, IGC has successfully obtained multiple patents and intellectual property rights, solidifying its position as a leading player in the medical cannabis space. The company's dedication to innovation and strategic partnerships has enabled it to pave the way for novel treatments and carve a niche for itself in the market.

India Globalization Capital Inc. (IGC) is a prominent company founded in 2005. The company primarily operates in various sectors like infrastructure, plant extraction, and traditional Chinese medicine. With a vision to become a global leader, IGC focuses on informational technology-related products and services to fulfill evolving market needs. Throughout its history, IGC has successfully developed and commercialized a range of patented therapies, enhancing consumer healthcare experiences and quality of life. The company's commitment to innovation and diversified business portfolio have contributed to its substantial growth and recognition within the industry. IGC continues to strive towards providing cutting-edge solutions and driving positive advancements in various fields of operation.

The main competitors of India Globalization Capital Inc in the market include companies such as Canopy Growth Corporation, Aurora Cannabis Inc, and Tilray Inc. These companies operate in the same industry and compete with India Globalization Capital Inc in areas such as cannabis-based pharmaceuticals, and alternative therapies and treatment solutions. India Globalization Capital Inc aims to differentiate itself through its proprietary intellectual property and innovative approaches in the market. However, it faces strong competition from these established players who also have a significant market presence and drive advancements in the industry.

India Globalization Capital Inc is primarily active in the industries of infrastructure, real estate, and pharmaceuticals.

The business model of India Globalization Capital Inc (IGC) revolves around various sectors, including infrastructure, technologies, and pharmaceuticals. IGC primarily focuses on the development and commercialization of cannabis-based therapies to address various medical conditions. By leveraging their in-house research and expertise, IGC aims to create innovative cannabis formulations that can potentially improve patient outcomes and quality of life. Additionally, the company also engages in the leasing of heavy equipment, mining exploration, and reclamation of high-grade iron ore to generate sustainable revenue. Through their diversified business segments, IGC strives to deliver value to its shareholders and contribute to the evolving medical and infrastructure sectors.

IGC Pharma KGV ir -1,58.

IGC Pharma KUV ir 15,25.

AlleAktien kvalitātes vērtējums IGC Pharma ir 4/10.

IGC Pharma apgrozījums ir 1,35 milj. USD.

IGC Pharma peļņa ir -13,00 milj. USD.

India Globalization Capital Inc. is a diversified company that operates in various industries including construction and infrastructure, heavy industry, agricultural and food production, as well as dietary supplements.

IGC Pharma izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt IGC Pharma vai uzņēmums nedod dividendes.

IGC Pharma ISIN ir US45408X3089.

IGC Pharma WKN ir A1T87A.

IGC Pharma simbols ir IGC.

Pēdējo 12 mēnešu laikā IGC Pharma maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos IGC Pharma plāno maksāt dividendes 0 USD apmērā.

IGC Pharma pašreizējā dividendu rentabilitāte ir .

IGC Pharma maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

IGC Pharma pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

IGC Pharma tiek piešķirts nozarei "Industrija".

Lai saņemtu pēdējo dividendu IGC Pharma apmērā 0 USD, kas tika izmaksāta 20.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 20.09.2024..

Pēdējās dividendes izmaksa notika 20.09.2024..

Gadā 2023, IGC Pharma izmaksāja 0 USD dividendes.

IGC Pharma dividendes tiek izmaksātas USD.